Built a fully integrated innovative 

biopharmaceutical company with capabilities in.

Drug discovery.

Drug development.

Construction of a pilot production facility in Nanjing.

Initiation of Phase III clinical trials for ONC-392.

ONC-782 enters the registration clinical trial phase.

Completed Series B financing.

Developed independently owned intellectual property for innovative products.

The AI-071 project entered the clinical stage.

The ONC-392 project entered Phase II clinical trials.